Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03669653
Other study ID # SERIC-AIS
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 17, 2024
Est. completion date September 20, 2026

Study information

Verified date February 2024
Source The First Hospital of Jilin University
Contact Yi Yang, MD, PhD
Phone 0086-13756661217
Email doctor_yangyi@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

he purpose of this study is to determine the efficacy and safety of remote ischemic conditioning for acute ischemic stroke.


Description:

In this study, 912 cases of ischemic stroke in 48 hours were included in 5 centers in China according to the principle of random, double-blind and parallel control .The experimental group receive basic treatment and remote ischemic conditioning for 200mmHg, 2 times per day for 7 consecutive days .The control group receive basic treatment and remote ischemic conditioning control for 60mmHg, 2 times per day, 7 days in a row . Two groups will be followed up for 90 days to evaluate the efficacy and safety of remote ischemic conditioning therapy.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 912
Est. completion date September 20, 2026
Est. primary completion date September 20, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - 1)Age=18 years, < 80 years, regardless of sex; - 2)Patients with clinically definite diagnosis of acute ischemic stroke and able to commence RIC treatment within 12 hours of stroke onset - 3)Baseline NIHSS score>5, and=25 ; - 4)GCS score =8; - 5)Signed and dated informed consent is obtained Exclusion Criteria: - 1) Patients with suspected posterior circulation infarction; - 2) Patients who undergo thrombolytic therapy or endovascular treatment; - 3) mRS=2 score before the onset of the disease; - 4) Double upper limbs or lower limbs paralysis was found in this case; - 5)Active bleeding of organs within 6 months of admission or current, including cerebral hemorrhage, subarachnoid hemorrhage, gastrointestinal hemorrhage, fundus hemorrhage and so on; - 6) Other intracranial lesions, such as cerebrovascular malformation cerebral venous diseases, tumor and other diseases involving the brain; - 7) Treated blood pressure =90mmHg/60mmHg or=180mmHg/100mmHg; - 8) Severe organ dysfunction or failure; - 9) Persons suffering from severe hematological diseases or severe coagulation disorder dysfunction; - 10) Those who had a history of severe trauma or had major surgery within 6 months prior to admission; - 11) The patients who had the contraindication of remote ischemic conditioning treatment, such as severe soft tissue injury, fracture or vascular injury in the upper limb;Acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc; - 12) Pregnant or lactating women; - 13) Previous remote ischemic conditioning therapy or similar treatment; - 14) Patients with a life expectancy of less than 3 months or patients unable to complete the study for other reasons; - 15) Severe hepatic and renal dysfunction - 16) Unwilling to be followed up or treated for poor compliance; - 17) He/She is participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to admission; - 18) Other conditions that the researchers think are not suitable for the group.

Study Design


Intervention

Procedure:
Remote ischemic conditioning
Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days.
Sham remote ischemic conditioning
Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 days.

Locations

Country Name City State
China First Hospital of Jilin University Changchun Jilin

Sponsors (1)

Lead Sponsor Collaborator
Yi Yang

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients with Modified Rankin Scale (mRS) Score 0-2 The primary outcome measure of efficacy is the modified Rankin Scale (mRS) dichotomized to define good functional outcome as mRS 0-2 at 90 days.score, dichotomized to define good functional outcome as mRS 0-2 at 90 days. 3 months
Secondary NIHSS Score at end of 7th day of treatment NIHSS Score at end of 7th day of treatment 7 days
Secondary mRS Score at end of 7th day of treatment mRS Score at end of 7th day of treatment 7 days
Secondary Barthel Index at end of 7th day of treatment Barthel Index at end of 7th day of treatment 7 days
Secondary Changes of hematological indicators The changes of hematological indicators (inflammatory cytokine,et al.) between the first 48h and end of 7th day of treatment. 48h; 7days
See also
  Status Clinical Trial Phase
Recruiting NCT06113848 - Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy Phase 3
Completed NCT04069546 - The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency N/A
Active, not recruiting NCT05700097 - Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy Phase 2
Recruiting NCT06058130 - Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis N/A
Recruiting NCT04415164 - Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke Phase 4
Recruiting NCT05363397 - Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke Phase 2
Completed NCT05429658 - Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System N/A
Recruiting NCT05390580 - Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct N/A
Enrolling by invitation NCT05515393 - A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke Phase 2
Active, not recruiting NCT05070260 - ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo Phase 2/Phase 3
Terminated NCT05547412 - Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
Completed NCT03366818 - New Stent Retriever, VERSI System for AIS N/A
Not yet recruiting NCT06040476 - Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS) Phase 2
Not yet recruiting NCT05293080 - Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE Phase 3
Completed NCT02223273 - Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke) N/A
Completed NCT02586233 - Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke Phase 1/Phase 2
Not yet recruiting NCT01594190 - Physical Activity Immediately After Acute Cerebral Ischemia N/A
Terminated NCT01694381 - Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor Early Phase 1
Completed NCT01120301 - Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3) Phase 3
Completed NCT01021319 - Identification of Stroke Patients ≤ 3 and ≤ 4.5 Hours of Symptom Onset by Fluid Attenuated Inversion Recovery (FLAIR) Imaging and Diffusion Weighted Imaging (DWI)